Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry

Mauri, 2005, Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis, J Natl Cancer Inst, 97, 188, 10.1093/jnci/dji021 Bonadonna, 1993, Preoperative chemotherapy in operable breast cancer, Lancet, 341, 1485, 10.1016/0140-6736(93)90933-8 Cortazar, 2014, Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, Lancet, 384, 164, 10.1016/S0140-6736(13)62422-8 von Minckwitz, 2012, Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes, J Clin Oncol, 30, 1796, 10.1200/JCO.2011.38.8595 Berruti, 2008, Presurgical systemic treatment of nonmetastatic breast cancer: facts and open questions, Oncologist, 13, 1137, 10.1634/theoncologist.2008-0162 Gianni, 2010, Lancet, 375, 377, 10.1016/S0140-6736(09)61964-4 Buzdar, 2005, Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer, J Clin Oncol, 23, 3676, 10.1200/JCO.2005.07.032 Simon, 2001, Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer, J Natl Cancer Inst, 93, 1141, 10.1093/jnci/93.15.1141 Gancberg, 2002, Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites, Ann Oncol, 13, 1036, 10.1093/annonc/mdf252 Simmons, 2009, Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?, Ann Oncol, 20, 1499, 10.1093/annonc/mdp028 Thompson, 2010, Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence in Tissues Study (BRITS), Breast Cancer Res, 12, R92, 10.1186/bcr2771 Lower, 2008, HER-2/neu expression in primary and metastatic breast cancer, Breast Cancer Res Treat, 113, 301, 10.1007/s10549-008-9931-6 Burstein, 2003, Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study, J Clin Oncol, 21, 46, 10.1200/JCO.2003.03.124 Hurley, 2006, Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer, J Clin Oncol, 24, 1831, 10.1200/JCO.2005.02.8886 Mittendorf, 2009, Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes, Clin Cancer Res, 15, 7381, 10.1158/1078-0432.CCR-09-1735 Niikura, 2012, Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors, J Clin Oncol, 30, 593, 10.1200/JCO.2010.33.8889 Fl, 2002, TNM Classification of Malignant Tumours, 131 Miyata, 2014, Challenges and prospects of a clinical database linked to the board certification system, Surg Today, 44, 1991, 10.1007/s00595-013-0802-3 Nagayama, 2014, Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis, J Natl Cancer Inst, 106, 10.1093/jnci/dju203 Sauter, 2009, Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations, J Clin Oncol, 27, 1323, 10.1200/JCO.2007.14.8197 Press, 2005, Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials, Clin Cancer Res, 11, 6598, 10.1158/1078-0432.CCR-05-0636 Paik, 2002, Real-world performance of HER2 testing—national surgical adjuvant breast and bowel project experience, J Natl Cancer Inst, 94, 852, 10.1093/jnci/94.11.852 Guarneri, 2013, Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients, Ann Oncol, 24, 2990, 10.1093/annonc/mdt364 Pusztai, 2010, Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis, Oncologist, 15, 1164, 10.1634/theoncologist.2010-0059 Kurebayashi, 2015, Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011, Breast Cancer, 22, 235, 10.1007/s12282-015-0599-6 Dekker, 2013, Reliability of core needle biopsy for determining ER and HER2 status in breast cancer, Ann Oncol, 24, 931, 10.1093/annonc/mds599